NAMS
NewAmsterdam Pharma Co N.V.
Key Financials
Operating Income
$-225683000
↓ 28.0%
Net Income
$-203819000
↑ 15.6%
Total Assets
$769.3M
↓ 11.0%
Revenue
$22.5M
↓ 50.6%
Total Liabilities
$85.9M
↓ 19.9%
Shareholders' Equity
$683.4M
↓ 9.8%
EPS (Diluted)
$-1.72
↑ 32.8%
Operating Cash Flow
$-147783000.00
↑ 6.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13D/A | 5/14/2026 | View on SEC |
| 8-K | 5/7/2026 | View on SEC |
| 10-Q | 5/7/2026 | View on SEC |
| SCHEDULE 13G/A | 5/6/2026 | View on SEC |
| ARS | 5/6/2026 | View on SEC |
| DEF 14A | 5/6/2026 | View on SEC |
| 8-K | 4/24/2026 | View on SEC |
| PRE 14A | 4/20/2026 | View on SEC |
| 4 | 3/12/2026 | View on SEC |
| 144 | 3/11/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | NAMS |
| Company Name | NewAmsterdam Pharma Co N.V. |
| CIK | 1936258 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | P7 |
| Phone | 35 206 2971 |